Cross-presentation: Underlying mechanisms and role in immune surveillance

Immunological Reviews

Volumn 207, Issue , 2005, Pages 166-183

  Rock, Kenneth L ^a   Shen, Lianjun ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN S; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; SUBUNIT VACCINE;

ANTIGEN PRESENTING CELL; CELL COMPARTMENTALIZATION; CELL DEATH; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CROSS PRESENTATION; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOPLASMIC RETICULUM; GENE MUTATION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; IN VIVO STUDY; NONHUMAN; PHAGOCYTOSIS; PHAGOSOME; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS; REVIEW; VIRUS INFECTION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; CROSS-PRIMING; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC SURVEILLANCE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 26244468314     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00301.x     Document Type: Review

References (167)

1. Rock KL, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-771.
2. Goldberg AL, Rock KL. Proteolysis, proteasomes and antigen presentation. Nature 1992;357:375-379.
3. Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem 1992;61:761-807.
4. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-479.
5. Pickart CM, Eddins MJ. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 2004;1695:55-72.
6. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999;17:739-779.
7. Kisselev AF, Akopian TN, Woo KM, Goldberg AL. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem 1999;274:3363-3371.
8. York IA, et al. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol 2002;3:1177-1184.
9. Saric T, et al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 2002;3:1169-1176.
10. Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 2002;419:480-483.
11. Goldberg AL, Cascio P, Saric T, Rock KL. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 2002;39:147-164.
12. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988;54:777-785.
13. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976;143:1283-1288.
14. Bevan MJ. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol 1976;117:2233-2238.
15. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986;44:959-968.
16. Rock KL, Fleischacker C, Gamble S. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant. J Immunol 1993;150:1244-1252.
17. Rock KL, Gamble S, Rothstein L, Gramm C, Benacerraf B. Dissociation of beta 2-microglobulin leads to the accumulation of a substantial pool of inactive class I MHC heavy chains on the cell surface. Cell 1991;65:611-620.
18. Falo LD, Kovacsovics-Bankowski M, Thompson K, Rock KL. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1995;1:649-653.
19. Rock KL, Clark K. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 1996;156:3721-3726.
20. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993;90:4942-4946.
21. Shi Y, Rock KL. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur J Immunol 2002;32:155-162.
22. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993;178:1391-1396.
23. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994;39:93-98.
24. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995;269:1585-1588.
25. Berwin B, Rosser MF, Brinker KG, Nicchitta CV. Transfer of GRP94 (Gp96)-associated peptides onto endosomal MHC class I molecules. Traffic 2002;3:358-366.
26. Singh-Jasuja H, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med 2000;191:1965-1974.
27. Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem 2001;276:17163-17171.
28. Blachere NE, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997;186:1315-1322.
29. Freigang S, Egger D, Bienz K, Hengartner H, Zinkernagel RM. Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming. Proc Natl Acad Sci USA 2003;100:13477-13482.
30. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-472.
31. Cho JH, Youn JW, Sung YC. Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 2001;167:5549-5557.
32. Shen L, Rock KL. Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci USA 2004;101:3035-3040.
33. Hilton CJ, Dahl AM, Rock KL. Anti-peptide antibody blocks peptide binding to MHC class I molecules in the endoplasmic reticulum. J Immunol 2001;166:3952-3956.
34. Serna A, Ramirez MC, Soukhanova A, Sigal LJ. Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells. J Immunol 2003;171:5668-5672.
35. + T cell cross-priming via transfer of proteasome substrates. Science 2004;304:1318-1321.
36. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN. Antigen bias in T cell cross-priming. Science 2004;304:1314-1317.
37. + T cells. Nat Immunol 2005;6:593-599.
38. Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 1990;249:918-921.
39. Rock KL, Rothstein L, Gamble S, Fleischacker C. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J Immunol 1993;150:438-446.
40. Grant EP, Rock KL. MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J Immunol 1992;148:13-18.
41. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997;158:2723-2730.
42. Kovacsovics-Bankowski M, Rock KL. Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines. Eur J Immunol 1994;24:2421-2428.
43. Inaba K, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998;188:2163-2173.
44. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
45. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
46. Rock KL, Rothstein L, Gamble S. Generation of class I MHC-restricted T-T hybridomas. J Immunol 1990;145:804-811.
47. + T cell responses to bacterial antigens. J Immunol 2004;173:1994-2002.
48. Heit A, Huster KM, Schmitz F, Schiemann M, Busch DH, Wagner H. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol 2004;172:1501-1507.
49. Ke Y, Kapp JA. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake. J Exp Med 1996;184:1179-1184.
50. Heath WR, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004;199:9-26.
51. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
52. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2:151-161.
53. Jung S, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002;17:211-220.
54. + T cells by infected dendritic cells in vivo. Nat Immunol 2002;3:265-271.
55. Pozzi L-AM, Maciaszek JW, Rock KL. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol 2005;175:2071-2081.
56. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004;5:1219-1226.
57. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000;192:1685-1696.
58. Belz GT, et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196:1099-1104.
59. den Haan JM, Bevan MJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med 2002;196:817-827.
60. + dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol 2003;170:4437-4440.
61. + dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 2004;172:1996-2000.
62. + dendritic cells but not by Langerhans cells. Science 2003;301:1925-1928.
63. + T cells stimulated by virus-induced type I interferon. Nat Immunol 2003;4:1009-1015.
64. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
65. Beignon AS, Skoberne M, Bhardwaj N. Type I interferons promote cross-priming: more functions for old cytokines. Nat Immunol 2003;4:939-941.
66. Norbury CC, Hewlett LJ, Prescott AR, Shastri N, Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 1995;3:783-791.
67. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 1994;153:4925-4933.
68. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993;361:359-362.
69. Carbone FR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990;171:377-387.
70. Li M, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001;166:6099-6103.
71. Bevan MJ. Antigen recognition. Class discrimination in the world of immunology. Nature 1987;325:192-194.
72. Reis e Sousa C, Germain RN. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med 1995;182:841-851.
73. Craiu A, et al. Lactacystin and clastolactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997;272:13437-13445.
74. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995;267:243-246.
75. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996;14:369-396.
76. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Arnigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999;1:362-368.
77. Oh YK, Harding CV, Swanson JA. The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I-restricted antigen presentation. Vaccine 1997;15:511-518.
78. Houde M, et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003;425:402-406.
79. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Arnigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003;425:397-402.
80. Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci USA 2003;100:12889-12894.
81. Gagnon E, et al. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell 2002;110:119-131.
82. Touret N, Paroutis P, Grinstein S. The nature of the phagosomal membrane: endoplasmic reticulum versus plasmalemma. J Leukoc Biol 2005;77:878-885.
83. Kopito RR. ER quality control: the cytoplasmic connection. Cell 1997;88:427-430.
84. Desjardins M. ER-mediated phagocytosis: a new membrane for new functions. Nat Rev Immunol 2003;3:280-291.
85. Rock KL. The ins and outs of cross-presentation. Nat Immunol 2003;4:941-943.
86. Roy CR. Immunology: professional secrets. Nature 2003;425:351-352.
87. Reits E, et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 2003;18:97-108.
88. Allen LA, Aderem A. Mechanisms of phagocytosis. Curr Opin Immunol 1996;8:36-40.
89. Desjardins M. Biogenesis of phagolysosomes: the 'kiss and run' hypothesis. Trends Cell Biol 1995;5:183-186.
90. Palliser D, Guillen E, Ju M, Eisen HN. Multiple intracellular routes in the cross-presentation of a soluble protein by murine dendritic cells. J Immunol 2005;174:1879-1887.
91. Song R, Harding CV. Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. J Immunol 1996;156:4182-4190.
92. Wick MJ, Pfeifer JD. Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Eur J Immunol 1996;26:2790-2799.
93. Campbell DJ, Serwold T, Shastri N. Bacterial proteins can be processed by macrophages in a transporter associated with antigen processing-independent, cysteine protease-dependent manner for presentation by MHC class I molecules. J Immunol 2000;164:168-175.
94. Shen L, Sigal LJ, Boes M, Rock KL. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 2004;21:155-165.
95. Stober D, Trobonjaca Z, Reimann J, Schirmbeck R. Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells. Eur J Immunol 2002;32:1099-1108.
96. Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 2002;32:818-825.
97. Bachmann MF, et al. TAP1-independent loading of class I molecules by exogenous viral proteins. Eur J Immunol 1995;25:1739-1743.
98. Chen L, Jondal M. Alternative processing for MHC dass I presentation by immature and CpG-activated dendritic cells. Eur J Immunol 2004;34:952-960.
99. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996;17:131-137.
100. Villadangos JA, et al. Proteases involved in MHC class II antigen presentation. Immunol Rev 1999;172:109-120.
101. Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997;59:63-88.
102. Deussing J, Roth W, Saftig P, Peters C, Ploegh HL, Villadangos JA. Cathepsins B and D are dispensable for major histocompatibility complex dass II-mediated antigen presentation. Proc Natl Acad Sci USA 1998;95:4516-4521.
103. Driessen C, Lennon-Dumenil AM, Ploegh HL. Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via Fcgamma receptors. Eur J Immunol 2001;31:1592-1601.
104. Hsieh CS, deRoos P, Honey K, Beers C, Rudensky AY. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J Immunol 2002;168:2618-2625.
105. Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem 1992;267:7258-7262.
106. Lennon-Dumenil AM, et al. Analysis of protease activity in live antigen-presenting cells shows regulation of the phagosomal proteolytic contents during dendritic cell activation. J Exp Med 2002;196:529-540.
107. Cho Y, Basta S, Chen W, Bennink JR, Yewdell JW. Heat-aggregated noninfectious influenza virus induces a more balanced CD8(+)-T-lymphocyte immunodominance hierarchy than infectious virus. J Virol 2003;77:4679-4684.
108. Schirmbeck R, Wild J, Reimann J. Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Eur J Immunol 1998;28:4149-4161.
109. Rock KL, Rothstein L, Gamble S, Gramm C, Benacerraf B. Chemical cross-linking of dass I molecules on cells creates receptive peptide binding sites. J Immunol 1992;148:1451-1457.
110. Chiu I, Davis DM, Strominger JL. Trafficking of spontaneously endocytosed MHC proteins. Proc Natl Acad Sci USA 1999;96:13944-13949.
111. Reid PA, Watts C. Cycling of cell-surface MHC glycoproteins through primaquine-sensitive intracellular compartments. Nature 1990;346:655-657.
112. Sugita M, Brenner MB. Association of the invariant chain with major histocompatibility complex class I molecules directs trafficking to endocytic compartments. J Biol Chem 1995;270:1443-1448.
113. Vigna JL, Smith KD, Lutz CT. Invariant chain association with MHC class I. preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove. J Immunol 1996;157:4503-4510.
114. Day PM, Yewdell JW, Porgador A, Germain RN, Bennink JR. Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells. Proc Natl Acad Sci USA 1997;94:8064-8069.
115. Sheikh NA, et al. Differential requirements for CTL generation by novel immunostimulants: APC tropism, use of the TAP-independent processing pathway, and dependency on CD80/CD86 costimulation. Vaccine 2003;21:3775-3788.
116. Brewer JM, Pollock KG, Tetley L, Russell DG. Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles. J Immunol 2004;173:6143-6150.
117. Oh YK, Swanson JA. Different fates of phagocytosed particles after delivery into macrophage lysosomes. J Cell Biol 1996;132:585-593.
118. Cervi L, MacDonald AS, Kane C, Dzierszinski F, Pearce EJ. Cutting edge: dendritic cells copulsed with microbial and helminth antigens undergo modified maturation, segregate the antigens to distinct intracellular compartments, and concurrently induce microbe-specific Th1 and helminth-specific Th2 responses. J Immunol 2004;172:2016-2020.
119. Harding CV, Collins DS, Slot JW, Geuze HJ, Unanue ER. Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells. Cell 1991;64:393-401.
120. Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat Immunol 2005;6:107-113.
121. Imai J, Hasegawa H, Maruya M, Koyasu S, Yahara I. Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells. Int Immunol 2005;17:45-53.
122. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999;398:77-80.
123. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996;4:349-355.
124. Sigal LJ, Rock KL. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J Exp Med 2000;192:1143-1150.
125. + T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading. Immunology 2003;109:374-383.
126. Rescigno M, et al. Bacteria-induced neobiosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc Natl Acad Sci USA 1998;95:5229-5234.
127. Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 2004;304:1014-1018.
128. Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 2001;1:126-134.
129. Yewdell JW, Haeryfar SM. Understanding presentation of viral antigens to CD8(+) T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 2005;23:651-682.
130. Schumacher TN. Immunology. Accessory to murder. Nature 1999;398:26-27.
131. Yewdell JW, Hill AB. Viral interference with antigen presentation. Nat Immunol 2002;3:1019-1025.
132. Watts C, Amigorena S. Phagocytosis and antigen presentation. Semin Immunol 2001;13:373-379.
133. Mazzaccaro RJ, et al. Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1996;93:11786-11791.
134. Lenz LL, Butz EA, Bevan MJ. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens. J Exp Med 2000;192:1135-1142.
135. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001;166:3717-3723.
136. Rock KL, Hearn A, Chen CJ, Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol 2005;26:231-246.
137. Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci USA 2000;97:14590-14595.
138. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-521.
139. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-305.
140. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
141. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002;2:965-975.
142. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003;23:15-44.
143. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002;23:509-512.
144. Kuppner MC, et al. The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol 2001;31:1602-1609.
145. Somersan S, Larsson M, Fonteneau JF, Basu S, Srivastava P, Bhardwaj N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 2001;167:4844-4852.
146. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000;12:1539-1546.
147. Singh-Jasuja H, et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol 2000;30:2211-2215.
148. Bethke K, et al. Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J Immunol 2002;169:6141-6148.
149. Millar DG, et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med 2003;9:1469-1476.
150. + cells in vivo. J Immunol 2000;165:6029-6035.
151. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002;2:185-194.
152. Srivastava PK, Amato RJ. Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents. Vaccine 2001;19:2590-2597.
153. Gao B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J Biol Chem 2003;278:174-179.
154. Gao B, Tsan MF. Recombinant human heat shock protein 60 does not induce the release of tumor necrosis factor alpha from murine macrophages. J Biol Chem 2003;278:22523-22529.
155. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004;76:514-519.
156. Bausinger H, et al. Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur J Immunol 2002;32:3708-3713.
157. Messmer D, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004;173:307-313.
158. Hunter RL. Overview of vaccine adjuvants: present and future. Vaccine 2002;20:S7-S12.
159. Dresser DW. Effectiveness of lipid and lipidophilic substances as adjuvants. Nature 1961;191:1169-1171.
160. Heath WR, Kurts C, Miller JF, Carbone FR. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med 1998;187:1549-1553.
161. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997;186:239-2345.
162. Horwitz MS, Ilic A, Fine C, Rodriguez E, Sarvetnick N. Presented antigen from damaged pancreatic beta cells activates autoreactive T cells in virus-mediated autoimmune diabetes. J Clin Invest 2002;109:79-87.
163. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998;188:409-414.
164. Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vaccines. Nat Biotechnol 1998;16:1025-1031.
165. Moron G, Dadaglio G, Leclerc C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol 2004;25:92-97.
166. Celluzzi CM, Falo LD Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998;160:3081-3085.
167. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 2005;17:163-169.